GLUT1 was essential for the maintenance of pancreatic, ovarian, and glioblastoma CSCs, and a specific GLUT1 inhibitor inhibited the functionality of CSCs and, in vivo, it delayed tumor initiation after the implantation of CSCs [110]. Here, SLC2A1 is linked to neoplasm.